<div class="wrapper wrapper-5">
  <h1 class="pt-5">CLINICAL REASEARCH</h1>
</div>
<div class="container">
  <div class="row mx-auto text-justify py-3">
    The GFAOP demonstrated that, even in Africa, clinical research could be done prospectively and multicentre. 5 tumor committees, one for each type of cancer, manage clinical studies and care protocol adaptations.
    Clinical researchers collect data that is analyzed and centralized in Gustave Roussy.
  </div>
  <div class="row mx-auto text-justify py-3">
    The objective of this medical research program is also to improve knowledge of pediatric cancers in French-speaking Africa : observed incidence of pediatric cancers in pilot units, comorbidities, feasibility of treatments, particular tolerance, treatment efficacy (survival rate, relapse cause, death cause, reasons for non-compliance with treatments, etc.). 
  </div>
  <div class="row">
    <div class="col-12 col-md-6 text-justify">
      There are 5 types of cancer that are treated under GFAOP.
      They account for about 70% of local cancers with a high chance of remission when treated early enough :
      <ul>
        <li>Nephroblastoma (kidney cancer)</li>
        <li>Retinoblastoma (eye cancer)</li>
        <li>Acute lymphoblastic leukemia</li>
        <li>Hodgkin's disease</li>
        <li>Burkitt's lymphoma</li>
      </ul>
    </div>
    <div class="col-12 col-md-6">
      <img src="patients_pathologie.png" class="borderless rounded img-thumbnail" alt="pathologies repartition" >
    </div>
  </div>
  <div class="row mx-auto text-justify py-4">
    <div class="col-12 col-md-6">
      <h4 class="text-left"><b>Cancer registry and data management</b></h4>
      Since January 2016, with the support of the Sanofi Espoir Foundation, a new patient data collection system has been set up with the objective of improving knowledge of pediatric cancers in the 16 countries (Observed incidence in experimental units, feasibility of treatment, reasons for non-compliance, causes of early death and morbidity). Each unit is asked to register its patients in a common software. Based on this information, new clinical research projects can be conducted to improve treatment protocols.
    </div>
    <div class="col-12 col-md-6 rounded">
      <img src="patients_inclusion.png" class="borderless rounded img-thumbnail" alt="inclusion repartition per country" >
    </div>
  </div>
</div>


<hr class="separator">
<div class="container">
  <h3 class="text-center py-3">Tumor Committees</h3>
  <div class="row text-center">
    <div class="col-12 col-md-3 cream rounded m-2 ml-md-auto">
      <h4 class="py-1">Burkitt Committee</h5>
      <h6>Coordinator : Maria El Kababri (Rabat, Marocco)</h6>
      <h6>Data manager : Marie-Anne Raquin (IGR, France)</h6>
      <h6>Secretary : Angèle Pondy (Yaoundé, Cameroon)</h6>
      <h6>Expert: Catherine Patte (IGR, France)</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2">
      <h4 class="py-1">Nephroblastoma Committee</h5>
      <h6>Coordinator : Claude Moreira (Dakar, Senegal)</h6>
      <h6>Data manager : Brenda Mallon (IGR, France)</h6>
      <h6>Secretary : Jean Jacques Atteby (Treichville, Ivory Coast)</h6>
      <h6>Expert: Catherine Patte (IGR, France)</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2 mr-md-auto">
      <h4 class="py-1">Retinoblastoma Committee</h5>
      <h6>Coordinator : Fousseyni Traoré (Bamako, Mali)</h6>
      <h6>Expert : Pierre Bey (Curie, France)</h6>
    </div>
  </div>
  <div class="row text-center">
    <div class="col-12 col-md-3 cream rounded m-2 ml-md-auto">
      <h4 class="py-1">Hodgkin lymphoma committee</h5>
      <h6>Coordinator : Christine Edan (Rennes, France)</h6>
      <h6>Data manager : Souad Nafa (IGR, France)</h6>
      <h6>Expert : Odile Oberlin</h6>
    </div>
    <div class="col-12 col-md-3 cream rounded m-2 mr-md-auto">
      <h4 class="py-1">Leukemia Acute Lymphoblastic Committee</h5>
      <h6>Coordinator : Marie Dominique Tabone</h6>
      <h6>Data manager : Clinical Research Unit (Trousseau, France)</h6>
      <h6>Expert : Guy Leverger (Armand Trousseau hospital)</h6>
    </div>
  </div>
</div>

<hr class="separator">

<div class="container">
  <h4 class="text-center py-2">The clinical studies conducted since the creation of the GFAOP show encouraging results.</h4>
  <div class="row text-justify">
    <div class="col-12 col-md-6">
      <img src="cas_declares.png" class="borderless rounded img-thumbnail" alt="graphic for declared cases" >
    </div>
    <div class="col-12 col-md-6">
      <p>Thus, for Burkitt and nephroblastoma, two successive studies carried out between 2000 and 2009 indicate the following survival rates :</p>
      <p>- 60% for Burkitt's Lymphomas (study directed by Professor Catherine Patte from the IGR and Dr Maria El Kababri from Rabat)</p>
      <p>- 70% for nephroblastomas (study directed by Professor Catherine Patte from the IGR and Professor Claude Moreira from Dakar)</p>
      <p>- For Hodgkin's disease, overall survival was 82% in our 2006-2012 study over 89 cases.</p>
    </div>
    <div class="col-12 col-md-6">
      <p>- For acute lymphoblastic leukemias, the latest study conducted by the GFAOP, with the expertise of Professor Guy Leverger from Armand Trousseau Hospital in Paris, shows a disease-free survival rate in sub-Saharan Africa of 60% at the end of the treatment, whose total duration is two years.</p>
      <p>- For retinoblastomas, 112 cases have observed in Bamako since the launch of the program in October 2011 with more than 90% healing.</p>
    </div>
    <div class="col-12 col-md-6">
      <img src="total_cas_declares.png" class="borderless rounded img-thumbnail" alt="graphique des totaux des cas declarés" >
    </div>
  </div>
  <div class="row text-justify">
    <img src="graphique_recapitulatif.png" class="borderless rounded img-thumbnail mx-auto" alt="graphique recapitulatif" >
  </div>
</div>
